Sanofi Stumps Up $125m To Access Denali RIPK1 Inhibitors
The French drugmaker is dipping its toe into Alzheimer's disease as part of a CNS and inflammatory alliance with Denali which could net the US firm $1bn on top of a hefty upfront fee.
You may also be interested in...
Biogen will pay Denali $560m up front plus a $465m equity investment in exchange for co-development and co-commercialization rights to clinical-stage LRRK2 inhibitors for Parkinson's disease.
Blueprint and Zymeworks raise $300m-plus in follow-on offerings. Also, Arcutis, Black Diamond and Annovis bring the 2020 US IPO count to four; Spring Bank, Surface Oncology and Decibel reveal strategic shifts; and Harmony’s $200m in venture debt leads recent VC deals.
A couple of years after Ipsen returned the rights to an LRRK2 Parkinson's program, Oncodesign has bagged a new partner in Servier and stands to bank up to €320m if all goes well.